<div id="readability-page-1"><p>JPMorgan Chase &amp; Co. grew its position in  Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 1,021.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,165 shares of the company's stock after purchasing an additional 61,174 shares during the period. JPMorgan Chase &amp; Co. owned about 0.23% of Aerovate Therapeutics worth $178,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Aerovate Therapeutics</strong> alerts:</span></p></div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Corient Private Wealth LLC bought a new stake in shares of  Aerovate Therapeutics in the fourth quarter worth about $98,000.  Ieq Capital LLC acquired a new position in shares of  Aerovate Therapeutics in the 4th quarter valued at approximately $38,000.  Deltec Asset Management LLC bought a new stake in  Aerovate Therapeutics during the 4th quarter worth approximately $514,000.  FNY Investment Advisers LLC bought a new stake in  Aerovate Therapeutics during the 4th quarter worth approximately $198,000.  Finally, Barclays PLC raised its holdings in  Aerovate Therapeutics by 310.8% during the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock worth $39,000 after buying an additional 14,354 shares during the period. </p><h2>Aerovate Therapeutics Stock Up 24.8 %</h2><p>Shares of AVTE stock opened at $12.48 on Monday. Aerovate Therapeutics, Inc. has a 12-month low of $43.75 and a 12-month high of $884.98. The firm has a fifty day moving average of $82.82 and a 200-day moving average of $86.86. The company has a market capitalization of $361.73 million, a price-to-earnings ratio of -4.17 and a beta of 0.95. </p><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $7.35.  On average, equities analysts expect that  Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year. </p><h2>Aerovate Therapeutics Dividend Announcement</h2><p>The firm also recently disclosed a  dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date  was Tuesday, April 29th. </p><h2>About Aerovate Therapeutics</h2> (Free Report)<p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p><h2>See Also</h2><ul><li>Five stocks we like better than Aerovate Therapeutics</li><li>When to Sell a Stock for Profit or Loss</li><li>Western Digital: Is the Storage Sector Set for a Rebound?</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>Wingstop Stock Jumps on Q1 Beat, Expansion Outlook</li><li>How to Capture the Benefits of Dividend Increases</li><li>Why Energy Stocks Like Exxon and Hess Are Back in Focus</li></ul><p><strong>Want to see what other hedge funds are holding AVTE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AVTE

<p>JPMorgan Chase & Co. increased its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 1,021.1% in Q4, owning 67,165 shares valued at $178,000. Other institutional investors also acquired stakes in the company. Aerovate's stock rose 24.8%, opening at $12.48, with a market cap of $361.73 million. The company reported a quarterly EPS of ($3.15), exceeding estimates. Aerovate focuses on developing treatments for rare cardiopulmonary diseases and recently announced a dividend of $84.00.</p>

JPMorgan Chase & Co. Has $178,000 Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)